Henry Long PhD

Henry Long received a BS from MIT and a Ph.D. in Chemistry from UC Berkeley. As a member of the pharmaceutical industry for more than 10 years, he is well-versed in target selection and validation in cancer biology and many other disease areas. In addition, he has spent a considerable amount of time evaluating and employing a variety of technologies for identifying genomic biomarkers in numerous clinical and pre-clinical programs.

At the Dana-Farber Cancer Institute, he acquired extensive experience in cancer epigenetics and has contributed to the characterization of the androgen receptor cistrome in prostate cancer and has applied single-cell approaches to study intratumor heterogeneity. As the Scientific Director of the Center for Functional Cancer Epigenetics, he has applied state-of-the-art epigenetics technologies to identify enhancers and other non-coding annotations in the human genome. Additionally, the Center has developed and applied state-of-the-art analysis pipelines to extract value from complex integrative genomics studies and support reproducible research efforts.